Properties (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Ranbaxy_Laboratories
U.S._based_companies |
| gptkbp:awards |
various industry awards
|
| gptkbp:budget |
publishes yearly
|
| gptkbp:CEO |
Seigo Kato
|
| gptkbp:clinicalTrials |
invests heavily
conducts globally |
| gptkbp:collaborations |
with academic institutions
|
| gptkbp:community_involvement |
supports health initiatives
|
| gptkbp:employees |
approximately 7,000
|
| gptkbp:facilities |
multiple locations worldwide
|
| gptkbp:founded |
1901
|
| gptkbp:founder |
gptkb:Kōsuke_Matsumoto
|
| gptkbp:has_a_focus_on |
research and development
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Daiichi Seiyaku
|
| gptkbp:investmentFocus |
provides updates regularly
|
| gptkbp:market |
growing_in_Europe
expanding_in_North_America strong_in_Asia |
| gptkbp:operates_in |
global market
|
| gptkbp:partnerships |
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Merck_&_Co. gptkb:Eli_Lilly_and_Company various global pharmaceutical companies |
| gptkbp:patentCitation |
numerous pharmaceutical patents
|
| gptkbp:productLine |
diverse and innovative
|
| gptkbp:products |
prescription drugs
over-the-counter medications |
| gptkbp:research_areas |
diabetes
oncology vaccines central nervous system disorders cardiovascular diseases infectious diseases pain management gastroenterology |
| gptkbp:revenue |
approximately $10 billion
|
| gptkbp:social_responsibility |
active in community health
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:subsidiary |
gptkb:Daiichi_Sankyo_Company,_Limited
|
| gptkbp:sustainability_initiatives |
environmental responsibility programs
|
| gptkbp:tactics |
focus on innovation
collaborate with healthcare providers enhance patient access expand therapeutic areas |
| gptkbp:website |
www.daiichiseiyaku.co.jp
|